

Frédéric Liot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9297354/publications.pdf>

Version: 2024-02-01

69
papers

5,113
citations

172457

29
h-index

155660

55
g-index

81
all docs

81
docs citations

81
times ranked

5508
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658.	3.4	23
2	Tissue microbiota: A "secondary-self", first target of autoimmunity?. <i>Joint Bone Spine</i> , 2022, 89, 105337.	1.6	6
3	Constriction ring syndrome: severe cuts. <i>Joint Bone Spine</i> , 2022, , 105415.	1.6	0
4	Grossesse et traitements de fond synthétiques. <i>Revue Du Rhumatisme Monographies</i> , 2021, 88, 70-75.	0.0	0
5	Imagerie du rhumatisme psoriasique. <i>Revue Du Rhumatisme Monographies</i> , 2020, 87, 261-266.	0.0	0
6	Adrenomedullin and truncated peptide adrenomedullin(22-52) affect chondrocyte response to apoptosis in vitro: downregulation of FAS protects chondrocyte from cell death. <i>Scientific Reports</i> , 2020, 10, 16740.	3.3	4
7	Recommandations de la Société française de rhumatologie pour la prise en charge de la goutte: le traitement hypo-uricémiant. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 332-341.	0.0	5
8	Recommandations 2020 de la Société française de rhumatologie pour la prise en charge de la goutte: traitement des crises de goutte. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 324-331.	0.0	4
9	UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis. <i>Joint Bone Spine</i> , 2020, 87, 647-651.	1.6	16
10	Lymphocyte Changes in Severe COVID-19: Delayed Over-Activation of STING?. <i>Frontiers in Immunology</i> , 2020, 11, 607069.	4.8	38
11	COVID-19 as a STING disorder with delayed over-secretion of interferon-beta. <i>EBioMedicine</i> , 2020, 56, 102801.	6.1	51
12	Galectin 3 Deficiency Alters Chondrocyte Primary Cilium Formation and Exacerbates Cartilage Destruction via Mitochondrial Apoptosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1486.	4.1	12
13	Biopsie de la graisse sous cutanée. <i>Revue Du Rhumatisme Monographies</i> , 2020, 87, 194-197.	0.0	0
14	Spondyloarthritis-Associated IgA Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 813-820.	0.8	12
15	2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares. <i>Joint Bone Spine</i> , 2020, 87, 387-393.	1.6	17
16	2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. <i>Joint Bone Spine</i> , 2020, 87, 395-404.	1.6	47
17	Gout: state of the art after a decade of developments. <i>Rheumatology</i> , 2019, 58, 27-44.	1.9	63
18	Gout furunculosis. <i>Joint Bone Spine</i> , 2019, 86, 103.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	3.4	73
20	Patients With Early-Onset Gout and Development of Earlier Severe Joint Involvement and Metabolic Comorbid Conditions: Results From a Cross-Sectional Epidemiologic Survey. <i>Arthritis Care and Research</i> , 2019, 71, 986-992.	3.4	22
21	Adsorption of Proteins on m-CPPD and Urate Crystals Inhibits Crystal-induced Cell Responses: Study on Albumin-crystal Interaction. <i>Journal of Functional Biomaterials</i> , 2019, 10, 18.	4.4	16
22	SAT0416...ULTRASOUND EVALUATION IN FOLLOW-UP OF URATE-LOWERING THERAPY IN GOUT PHASE 2 (USEFUL-2): DURATION OF FLARE PROPHYLAXIS. , 2019, , .		0
23	SAT0412...DOES THERAPEUTIC EDUCATION IMPROVE GOUT MANAGEMENT: THE EXPERIENCE OF LARIBOISIERE UNIVERSITY HOSPITAL PARIS-FRANCE. , 2019, , .		0
24	Non-pharmacologic measures for gout management in the prospective GOSPEL cohort: Physicians' practice and patients' compliance profiles. <i>Joint Bone Spine</i> , 2019, 86, 225-231.	1.6	2
25	Furonculose goutteuse. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019, 86, 206.	0.0	0
26	Reply to the comment of Mourgues et al., 2012. American guidelines for the management of gout as seen by general practitioners. <i>Joint Bone Spine</i> , 2019, 86, 279-280.	1.6	0
27	Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study. <i>Rheumatology</i> , 2019, 58, 410-417.	1.9	30
28	Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. <i>Joint Bone Spine</i> , 2018, 85, 755-760.	1.6	29
29	GOSPEL 3: prise en charge de la goutte par les médecins généralistes et rhumatologues libéraux en France au début du XXI ^e siècle. Comparaison aux recommandations EULAR 2006. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 165-172.	0.0	0
30	Osteopenia and fractures associated with long-term therapy with MEK inhibitors. <i>Melanoma Research</i> , 2018, 28, 641-644.	1.2	7
31	Inflammatory Potential of Four Different Phases of Calcium Pyrophosphate Relies on NF- κ B Activation and MAPK Pathways. <i>Frontiers in Immunology</i> , 2018, 9, 2248.	4.8	41
32	From hyperuricaemia to gout: what are the missing links?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 448-449.	8.0	13
33	«Sacroplastie» percutanée pour fracture du sacrum par insuffisance osseuse. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 175.	0.0	0
34	Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 281-287.	3.4	42
35	GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century—A comparison with 2006 EULAR Recommendations. <i>Joint Bone Spine</i> , 2017, 84, 447-453.	1.6	21
36	Percutaneous sacroplasty for sacral fracture by osteoporotic insufficiency. <i>Joint Bone Spine</i> , 2017, 84, 489.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). <i>Nature Reviews Rheumatology</i> , 2017, 13, 561-568.	8.0	74
38	Diagnostiquer et suivre le rachis cervical rhumatoïde. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 359-368.	0.0	0
39	Prevalence of Gout in the Adult Population of France. <i>Arthritis Care and Research</i> , 2016, 68, 261-266.	3.4	70
40	New therapeutic approach to hyperuricemia and gout in the light of recommendations. <i>Joint Bone Spine</i> , 2016, 83, 376-380.	1.6	4
41	Le «Âgenou microcristallinÂ» ou «Âarthropathies du genou associÃ©es aux maladies microcristallinesÂ». <i>Revue Du Rhumatisme Monographies</i> , 2016, 83, 144-149.	0.0	0
42	A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. <i>Journal of Rheumatology</i> , 2016, 43, 1724-1734.	2.0	175
43	Non-ÂTNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1172.	7.4	160
44	GOSPEL 2Â-ÂColchicine for the treatment of gout flares in FranceÂ-Âa GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age. <i>Joint Bone Spine</i> , 2016, 83, 687-693.	1.6	26
45	LÃ©flunomideÂ: inducteur de lupus cutanÃ© subaiguÂ?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 144-148.	0.0	1
46	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2557-2568.	5.6	393
47	Nouvelle approche du traitement de lâ€™hyperuricÃ©mie et de la goutte Â la lumiÃ©re des recommandations. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, A23-A26.	0.0	0
48	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1789-1798.	0.9	545
49	The status of strontium in biological apatites: anÂXANES/EXAFS investigation. <i>Journal of Synchrotron Radiation</i> , 2014, 21, 136-142.	2.4	43
50	Managing gout needs more than drugs: lâ€™il faut le savoir-faire, l'Art et la maniÃ©re</i>. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 791-793.	0.9	18
51	Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. <i>Arthritis Research and Therapy</i> , 2013, 15, R123.	3.5	103
52	Revisiting spatial distribution and biochemical composition of calcium-containing crystals in human osteoarthritic articular cartilage. <i>Arthritis Research and Therapy</i> , 2013, 15, R103.	3.5	49
53	Chondrocalcinosis of Femoro-Tibial and Proximal Tibio-Fibular Joints in Cadaveric Specimens: A High-Resolution CT Imaging Study of the Calcification Distribution. <i>PLoS ONE</i> , 2013, 8, e54955.	2.5	15
54	Pathogenic Role of Basic Calcium Phosphate Crystals in Destructive Arthropathies. <i>PLoS ONE</i> , 2013, 8, e57352.	2.5	92

#	ARTICLE	IF	CITATIONS
55	GOSPEL: Prospective survey of gout in France. Part I: Design and patient characteristics (n=1003). <i>Joint Bone Spine</i> , 2012, 79, 464-470.	1.6	52
56	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1447-1461.	3.4	598
57	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care and Research</i> , 2012, 64, 1431-1446.	3.4	1,268
58	Targeting Bone Alleviates Osteoarthritis in Osteopenic Mice and Modulates Cartilage Catabolism. <i>PLoS ONE</i> , 2012, 7, e33543.	2.5	43
59	Adrenomedullin ⁵² combats inflammation and prevents systemic bone loss in murine collagen-induced arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1069-1081.	6.7	12
60	Adrenomedullin, a neuropeptide with immunoregulatory properties induces semi-mature tolerogenic dendritic cells. <i>Immunology</i> , 2012, 136, 252-264.	4.4	29
61	Articular cartilage calcification in osteoarthritis: Insights into crystal-induced stress. <i>Arthritis and Rheumatism</i> , 2011, 63, 10-18.	6.7	134
62	Basic Calcium Phosphate Crystals Induce Monocyte/Macrophage IL-1 ² Secretion through the NLRP3 Inflammasome In Vitro. <i>Journal of Immunology</i> , 2011, 186, 2495-2502.	0.8	226
63	Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1533-1538.	0.9	75
64	Traitement de l'agoutte. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 160-167.	0.0	15
65	Recent developments in crystal-induced inflammation pathogenesis and management. <i>Current Rheumatology Reports</i> , 2007, 9, 243-250.	4.7	19
66	A Critical Role for Adrenomedullin-Calcitonin Receptor-Like Receptor in Regulating Rheumatoid Fibroblast-Like Synoviocyte Apoptosis. <i>Journal of Immunology</i> , 2006, 176, 5548-5558.	0.8	33
67	Octacalcium phosphate crystals directly stimulate expression of inducible nitric oxide synthase through p38 and JNK mitogen-activated protein kinases in articular chondrocytes. <i>Arthritis Research and Therapy</i> , 2005, 7, R915.	3.5	68
68	Cervical spine involvement in rheumatoid arthritis. A review. <i>Joint Bone Spine</i> , 2002, 69, 141-154.	1.6	105
69	Inhibition and prevention of monosodium urate monohydrate crystal-induced acute inflammation in vivo by transforming growth factor β 1. <i>Arthritis and Rheumatism</i> , 1996, 39, 1192-1198.	6.7	70